Cool site pour acheter des pilules http://achetermedicaments2014.com/ Ne pas se perdre venir sur.
Microsoft word - ceftriaxone_study_2010.docx
Title: Clinical Trial of Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)
Principal Investigator: Merit Cudkowicz, MD, MSc., Professor of Neurology, Harvard Medical
School, Massachusetts General Hospital
Contact: Sarah Titus, MPH (617) 726-1398 firstname.lastname@example.org
This trial is currently enrolling
Primary Outcome Measures:
evaluation of multiple upper extremity muscles using hand held dynamometry
long-term safety and tolerability of ceftriaxone
Estimated Enrollment: 600 Study Start Date: July 2006 Estimated Study Completion Date: June 2012 Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure) Detailed Description: It is known that nerve cells called motor neurons die in the brains and spinal cords of people with amyotrophic lateral sclerosis (ALS). However, the cause of this cell death is unknown. Researchers think that increased levels of a chemical called "glutamate" may be related to the cell death. For this reason researchers want to study drugs that decrease glutamate levels near nerves. Ceftriaxone—a semi-synthetic, third generation cephalosporin antibiotic—may increase the level of a protein that decreases glutamate levels near nerves. Studies of ceftriaxone in the laboratory suggest that it may protect motor neurons from injury.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years. The goals of this study are to evaluate the safety and effectiveness of ceftriaxone as a treatment for ALS, and to determine the safety and effectiveness of long-term use of the drug in people with ALS.
A total of 600 eligible people with ALS will be enrolled in this multi-center research study. Participants will be randomly assigned to receive treatment with ceftriaxone (2/3 of participants) or placebo (1/3 of participants) for at least 12 months.
The study consists of three stages. The first stage, which has completed enrollment, will look at whether ceftriaxone enters the cerebrospinal fluid (the fluid that surrounds the spinal cord, also called CSF) in amounts that are high enough to be of possible benefit. The second stage, which
has also completed enrollment, will look at the safety and side effects of the study drug when taken daily for at least 20 weeks. The study is currently enrolling subjects for the third stage, which began in Spring 2009, and will determine whether the study drug prolongs survival and slows decline in function due to ALS.
Ages Eligible for Study: 18 Years and older
Genders Eligible for Study: Both
Accepts Healthy Volunteers: No Criteria **This is a partial list. Please check with the nearest site to review the full eligibility criteria.**
Participants will be people with ALS, at least 18 years of age.
Participants must be medically able to undergo the study procedures and have a caregiver or other individual who will be available to help with daily study medication administration.
Participants should live within a reasonable distance of the study site, due to frequent study visits.
Participants cannot be taking any other experimental medications for ALS, or have a history of sensitivity to cephalosporin antibiotics (such as Ancef, Keflex, Ceclor, Ceftin, Lorabid, Suprax, or Fortaz).
Locations: Please visit the NEALS Website for a complete list of site locations - http://www.alsconsortium.org/nealsclinicalresearch_Ceftriaxone.html
Location information is also available on the clinicaltrials.gov website - http://www.clinicaltrials.gov/ct2/show/NCT00349622?term=ALS+Ceftriaxone&rank=1
Gynecological Endocrinology, December 2007; 23(12): 700–703Myo-inositol in patients with polycystic ovary syndrome: A novelmethod for ovulation inductionENRICO PAPALEO1, VITTORIO UNFER2, JEAN-PATRICE BAILLARGEON3,LUCIA DE SANTIS1, FRANCESCO FUSI1, CLAUDIO BRIGANTE1, GUIDO MARELLI1,ILARIA CINO1, ANNA REDAELLI1, & AUGUSTO FERRARI11IVF Unit, Gynaecological-Obstetric Department, IRCCS San R
4, PHARMA COMPLEX, B/h MARKETING YARD, Wadhwancity–363035 Phone No.:(02752) 242072,41511,241783 Fax No.: 241169 Website : www.excarelab.com Email : email@example.com (W.E.F. JULY – 2010) ANTIBIOTICS & ANTIBACTERIALS Product Composition (I.O.A.T.) Fasst–200-DT Fasst – 100 - DT Fasst - 50 -DT Fasst - 50 Zimetile – S – 1 Cefoperazone 500 mg.+